Immunology of Infectious Disease News Volume 9.09 | Mar 10 2021

    0
    37






    IIDN 9.09 | Mar 10 2021


    Immunology of Infectious Disease News by STEMCELL Technologies
    Vol. 9.09 – 10 March, 2021
    TOP STORY

    Resistance of SARS-CoV-2 Variants to Neutralization by Monoclonal and Serum-Derived Polyclonal Antibodies

    Using monoclonal antibodies (mAbs), animal immune sera, human convalescent sera and human sera from recipients of the BNT162b2 mRNA vaccine, scientists report the impact on antibody neutralization of a panel of authentic SARS-CoV-2 variants.
    [Nature Medicine]

    Full Article

    Download the cell separation e-book, a practical guide on everything you need to know about cell isolation techniques.
    PUBLICATIONSRanked by the impact factor of the journal

    Genome-Wide CRISPR Screening Identifies TMEM106B as a Proviral Host Factor for SARS-CoV-2

    Investigators discovered that SARS-CoV-2 required the lysosomal protein TMEM106B to infect human cell lines and primary lung cells.
    [Nature Genetics]

    Full Article

    Robust SARS-CoV-2-Specific T Cell Immunity Is Maintained at Six Months Following Primary Infection

    The authors analyzed the magnitude and phenotype of the SARS-CoV-2-specific T cell response in 100 donors at six months following infection.
    [Nature Immunology]

    Full Article

    SARS-CoV-2 Variant B.1.1.7 Is Susceptible to Neutralizing Antibodies Elicited by Ancestral Spike Vaccines

    Researchers showed that B.1.1.7 remained sensitive to neutralization, albeit at moderately reduced levels, by serum samples from convalescent individuals and recipients of an mRNA vaccine and a protein nanoparticle vaccine.
    [Cell Host & Microbe]

    AbstractFull ArticleGraphical Abstract

    The SARS-CoV-2 Subgenome Landscape and its Novel Regulatory Features

    Scientists revealed the subgenome landscape of SARS-CoV-2 and its regulatory features, providing a molecular basis for understanding subgenome biogenesis and developing novel anti-viral strategies.
    [Molecular Cell]

    AbstractFull ArticleGraphical Abstract

    SARS-CoV-2 Mutations in MHC-I-Restricted Epitopes Evade CD8+ T Cell Responses

    Investigators identified nonsynonymous mutations in MHC-I-restricted CD8+ T cell epitopes after deep sequencing of 747 SARS-CoV-2 virus isolates.
    [Science Immunology]

    Full Article

    Immunogenicity of Prime-Boost Protein Subunit Vaccine Strategies against SARS-CoV-2 in Mice and Macaques

    The authors assessed prototypic S and receptor binding domain subunit vaccines in homologous or heterologous prime-boost regimens in mice and non-human primates.
    [Nature Communications]

    Full Article

    Deciphering the State of Immune Silence in Fatal COVID-19 Patients

    Researchers showed a COVID-19 immune signature associated with severity by integrating single-cell RNA-seq analysis from blood samples and broncho-alveolar lavage fluids with clinical, immunological and functional ex vivo data.
    [Nature Communications]

    Full Article

    The Impact of Spike Mutations on SARS-CoV-2 Neutralization

    In this study scientists evaluated neutralization of a series of mutated Spike pseudotypes based on divergence from SARS-CoV and then compare neutralization of the B.1.1.7 Spike pseudotype and individual mutations.
    [Cell Reports]

    AbstractGraphical Abstract

    Broad Neutralization of H1 and H3 Viruses by Adjuvanted Influenza HA Stem Vaccines in Nonhuman Primates

    The authors showed that headless hemagglutinin stabilized-stem immunogens presented on ferritin nanoparticles elicited broadly neutralizing antibody responses to diverse H1 and H3 viruses in non-human primates when delivered with a squalene-based oil-in-water emulsion adjuvant, AF03.
    [Science Translational Medicine]

    Abstract

    B Cell Engagement with HIV-1 Founder Virus Envelope Predicts Development of Broadly Neutralizing Antibodies

    Scientists demonstrated that the initial B cell interaction with the founder HIV envelope was important for the development of broadly neutralizing antibodies.
    [Cell Host & Microbe]

    AbstractGraphical Abstract

    Acetylcholine Production by Group 2 Innate Lymphoid Cells Promotes Mucosal Immunity to Helminths

    Group 2 innate lymphoid cells were shown to synthesize and release acetylcholine during parasitic nematode infection.
    [Science Immunology]

    Full Article

    The ChAT-Acetylcholine Pathway Promotes Group 2 Innate Lymphoid Cell Responses and Anti-Helminth Immunity

    The authors identified that activated innate lymphoid cells (ILC2s) up-regulate choline acetyltransferase (ChAT)—the enzyme responsible for the biosynthesis of acetylcholine.
    [Science Immunology]

    Full Article

    Host-Microbe Cross-Talk Governs Amino Acid Chirality to Regulate Survival and Differentiation of B Cells

    Scientists report that amino acid chirality balanced by bacteria-mammal cross-talk modulated intestinal B cell fate and immunoglobulin A production.
    [Science Advances]

    Full Article

    New human primary cell products—frozen leukopaks, regulatory T cells, and more. Click to view products.
    REVIEWS

    COVID-19 and Liver Disease: Mechanistic and Clinical Perspectives

    The authors discuss the hepatotropism of SARS-CoV-2, including the differential expression of viral receptors on liver cell types.
    [Nature Reviews Gastroenterology & Hepatology]

    Full Article

    Virus Vaccines: Proteins Prefer Prolines

    Investigators review how the engineered viral proteins technique emerged during HIV-1 Env vaccine development and its subsequent wider application to other viral vaccines including SARS-CoV-2.
    [Cell Host & Microbe]

    Abstract

    COVID-19 in Early 2021: Current Status and Looking Forward

    Scientists summarize what they have learned in the following areas: epidemiology, virology, and pathogenesis, diagnosis, use of artificial intelligence in assisting diagnosis, treatment, and vaccine development.
    [Signal Transduction and Targeted Therapy]

    Full Article

    INDUSTRY AND POLICY NEWS

    CEPI and VBI Vaccines Collaborate to Advance Vaccine Candidates against COVID-19 Variants

    CEPI and VBI Vaccines, Inc. announced a partnership to develop VBI’s enveloped virus like particle vaccine candidates against SARS-CoV-2 variants, including the B.1.351 variant first identified in South Africa.
    [CEPI (BusinessWire, Inc)]

    Press Release

    AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase III Trial for Early COVID-19

    AbCellera announced that bamlanivimab 700 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company, and etesevimab 1400 mg together reduced COVID-19-related hospitalizations and deaths by 87% in high-risk patients recently diagnosed with COVID-19.
    [AbCellera (BusinessWire, Inc)]

    AbstractPress Release

    FEATURED EVENT

    Lipidomics of Health and Disease

    March 24 – 26, 2021
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Full Professor – Translational Infectiology and Vaccine Development

    Uni Tübingen- Tübingen, Germany

    Research Associate – COVID-19 Registry

    The University of British Columbia- Vancouver, British Columbia, Canada

    Assistant Professor – Infectious Diseases

    University of California Merced – Merced, California, United States

    Postdoctoral Fellow – Human COVID Immunology

    Oklahoma Medical Research Foundation – Oklahoma City, Oklahoma, United States

    Postdoctoral Researcher – 3D In Vitro Systems for Respiratory Bacterial Infections

    NCCR AntiResist – Basel, Switzerland

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Immunology of Infectious Disease News Twitter